Literature DB >> 9276378

Dose-volume histograms for bladder and rectum.

J Y Ting1, X Wu, J A Fiedler, C Yang, M L Watzich, A Markoe.   

Abstract

PURPOSE: A careful examination of the foundation upon which the concept of the Dose-Volume Histogram (DVH) is built, and the implications of this set of parameters on the clinical application and interpretation of the DVH concept has not been conducted since the introduction of DVHs as a tool for the quantitative evaluation of treatment plans. The purpose of the work presented herein is to illustrate problems with current methods of implementing and interpreting DVHs when applied to hollow anatomic structures such as the bladder and rectum. METHODS AND MATERIALS: A typical treatment plan for external beam irradiation of a patient with prostate cancer was chosen to provide a data set from which DVH curves for both the bladder and rectum were calculated. The two organs share the property of being shells with contents that are of no clinical importance. DVHs for both organs were computed using a solid model and using a shell model. Typical treatment plans for prostate cancer were used to generate DVH curves for both models. The Normal Tissue Complication Probability (NTCP) for these organs is discussed in this context.
RESULTS: For an eight-field conformal treatment plan of the prostate, a bladder DVH curve generated using the shell model is higher than the corresponding curve generated using the solid model. The shell model also has a higher NTCP. A six-field conformal treatment plan also results in a higher DVH curve for the shell model. A treatment plan consisting of bilateral 120-degree arcs, results in a higher DVH curve for the shell model, as well as a higher NTCP.
CONCLUSION: The DVH concept currently used in evaluation of treatment plans is problematic because current practices of defining exactly what constitutes "bladder" and "rectum." Commonly used methods of tracing the bladder and rectum imply use of a solid structure model for DVHs. In reality, these organs are shells and the critical structure associated with NTCP is obviously and indisputably the shell, as opposed to its contents. Treatment planning algorithms for DVH computation should thus be modified to utilize the shell model for these organs.

Entities:  

Mesh:

Year:  1997        PMID: 9276378     DOI: 10.1016/s0360-3016(97)00312-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Voxel-based population analysis for correlating local dose and rectal toxicity in prostate cancer radiotherapy.

Authors:  Oscar Acosta; Gael Drean; Juan D Ospina; Antoine Simon; Pascal Haigron; Caroline Lafond; Renaud de Crevoisier
Journal:  Phys Med Biol       Date:  2013-03-26       Impact factor: 3.609

2.  Dosimetric analysis and comparison of IMRT and HDR brachytherapy in treatment of localized prostate cancer.

Authors:  V Murali; P G G Kurup; P Mahadev; S Mahalakshmi
Journal:  J Med Phys       Date:  2010-04

3.  A tensor-based population value decomposition to explain rectal toxicity after prostate cancer radiotherapy.

Authors:  Juan David Ospina; Frédéric Commandeur; Richard Ríos; Gaël Dréan; Juan Carlos Correa; Antoine Simon; Pascal Haigron; Renaud de Crevoisier; Oscar Acosta
Journal:  Med Image Comput Comput Assist Interv       Date:  2013

4.  Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy.

Authors:  Alexandra J Stewart; Robert A Cormack; Hang Lee; Li Xiong; Jorgen L Hansen; Desmond A O'Farrell; Akila N Viswanathan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

5.  Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis.

Authors:  Ashesh B Jani; Christopher M Hand; Charles A Pelizzari; John C Roeske; Lani Krauz; Srinivasan Vijayakumar
Journal:  BMC Cancer       Date:  2003-05-13       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.